- Home
- PCRX vs ATRO Comparison
PCRX vs ATRO Comparison
Compare PCRX & ATRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- ATRO
- Stock Information
- Founded
- PCRX 2006
- ATRO 1968
- Country
- PCRX United States
- ATRO United States
- Employees
- PCRX N/A
- ATRO N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- ATRO Military/Government/Technical
- Sector
- PCRX Health Care
- ATRO Industrials
- Exchange
- PCRX Nasdaq
- ATRO Nasdaq
- Market Cap
- PCRX 1.2B
- ATRO 844.1M
- IPO Year
- PCRX 2011
- ATRO N/A
- Fundamental
- Price
- PCRX $23.21
- ATRO $32.53
- Analyst Decision
- PCRX Buy
- ATRO Hold
- Analyst Count
- PCRX 9
- ATRO 1
- Target Price
- PCRX $29.89
- ATRO $32.00
- AVG Volume (30 Days)
- PCRX 582.1K
- ATRO 670.4K
- Earning Date
- PCRX 07-29-2025
- ATRO 07-31-2025
- Dividend Yield
- PCRX N/A
- ATRO N/A
- EPS Growth
- PCRX N/A
- ATRO N/A
- EPS
- PCRX N/A
- ATRO N/A
- Revenue
- PCRX $702,772,000.00
- ATRO $816,288,000.00
- Revenue This Year
- PCRX $7.54
- ATRO $8.33
- Revenue Next Year
- PCRX $10.78
- ATRO $5.89
- P/E Ratio
- PCRX N/A
- ATRO N/A
- Revenue Growth
- PCRX 3.08
- ATRO 13.73
- 52 Week Low
- PCRX $11.16
- ATRO $14.13
- 52 Week High
- PCRX $29.33
- ATRO $36.32
- Technical
- Relative Strength Index (RSI)
- PCRX 35.28
- ATRO 51.65
- Support Level
- PCRX $23.24
- ATRO $32.90
- Resistance Level
- PCRX $24.36
- ATRO $34.60
- Average True Range (ATR)
- PCRX 0.74
- ATRO 1.67
- MACD
- PCRX -0.13
- ATRO -0.41
- Stochastic Oscillator
- PCRX 15.58
- ATRO 30.46
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About ATRO Astronics Corporation
Astronics Corp supplies products to the aerospace, defense, and electronics industries. The company has two reportable segments namely Aerospace and Test Systems. The aerospace segment serves three primary markets: military, commercial transport, and General Aviation. The Test Systems segment serves the aerospace, defense, and semiconductor markets. The company generates a majority of its revenue from the Aerospace segment. Geographically, it generates a majority of its revenue from the United States.